normative

Approval should require survival benefit over real standard of care

For a disease like multiple myeloma with 10-15 active drugs and 7-10 year median survival, drugs should not be approved on uncontrolled tumor-shrinkage studies; instead the bar should be improved survival over a real American standard of care, and ideally a clinically meaningful threshold (three to six months) that patients consider worthwhile.

normativepending

Speaker

Vinay Prasad

Evidence Quote

“if your new drug improves survival over a real standard of care we're giving in America, we'll approve it. And, if not, no.”

Source

Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty— EconTalk
Created: 6/13/2026, 3:32:57 AM

Your notes

Loading notes...